Blanket Purchase Agreement 36F79718D0566-36E79724A0003
Award Date
12/4/23
Last Date to Order
12/3/25
Federal Agency
National Acquisition Center
Awardee
Biogen U.s. Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule, with a ceiling value of $2,210,000,000 and a period of performance through September 2026. Biogen has been awarded multiple firm-fixed-price delivery orders against this FSS contract for the supply of specialized...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency under the Department of Veterans Affairs (VA), to Biocryst Pharmaceuticals Inc. The BPA has a ceiling value of $10,000,000 and an ultimate completion date of May 18, 2026. It is a single-award contract awarded under GSA Schedule 61-IB for Pharmaceuticals and Drugs, with no set-aside used. The BPA is for the procurement of two pharmaceutical products: RAPIVAB (peramivir),...
The federal contract IDV award is a Blanket Purchase Agreement (BPA) established by the National Acquisition Center, a civilian agency, with Horizon Therapeutics USA, Inc., a for-profit biotechnology company. The single-award BPA has a ceiling value of $31,375,000 and a performance period from September 2024 to September 2025. It is set up against the GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and allows VA medical centers and Veterans Integrated Service Networks (VISNs) to...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a component of the Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA, valued at $83.5 million, is for a one-year period from May 2024 to May 2025. The BPA covers the procurement of specialized medications used to treat pulmonary arterial hypertension, including Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, and...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to AbbVie US LLC, a subsidiary of AbbVie Inc. The BPA has a ceiling value of $12,000,000 and is set to expire on October 31, 2025. The primary purpose of this BPA is to provide the VA with Duopa, a medication used to treat Parkinson's disease. AbbVie US LLC, as the prime contractor, will deliver Duopa to VA medical centers across various Veterans...
The subject federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a division of the U.S. Department of Veterans Affairs (VA), to Amylyx Pharmaceuticals Inc. (Amylyx). The BPA, valued at $50,000, is for the procurement of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS) developed by Amylyx. As a self-certified small disadvantaged business, Amylyx has established several contract vehicles with the VA to facilitate the...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency, to Jazz Pharmaceuticals, Inc. The BPA, valued at $161,183,457.45, is set to expire on August 15, 2026 and is awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA enables the Department of Veterans Affairs (VA) to efficiently procure specialty pharmaceutical products from Jazz Pharmaceuticals, Inc., including the sleep disorder...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Chiesi USA Inc., a specialty pharmaceutical company. The BPA has a ceiling value of $2,250,000 and a period of performance through September 2025. The BPA is issued against Chiesi's Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs. Under this vehicle, Chiesi will provide the VA with the iron chelating drug Ferriprox and the...